average carbon chain length of about 20 to 30 carbon atoms, present in the amount of about 0.3 to 10 percent of the total weight of said polyether.

36. The composition of claim **35**, wherein the polyether is prepared using a proportion of ethylene oxide residue to the residue of said lower alkylene oxide of about 70 to about 90 percent by weight of ethylene oxide residue to about 30 to about 10 percent by weight of said lower alkylene oxide residue.

37. The composition of claim **36**, wherein said polyether is prepared using propylene oxide as the lower alkylene oxide.

38. The composition of claim **33**, wherein said polyether is prepared using a block copolymer intermediate.

39. The composition of claim **38**, wherein said polyether is prepared using an alpha-olefin oxide having an average carbon chain length of about 20 to 30 carbon atoms, present in the amount of about 0.3 to 10 percent of the total weight of said polyether.

40. The composition of claim **39**, wherein the polyether is prepared using a proportion of ethylene oxide residue to the residue of said lower alkylene oxide of about 70 to about 90 percent by weight of ethylene oxide residue to about 30 to about 10 percent by weight of said lower alkylene oxide residue.

41. The composition of claim **40**, wherein said polyether is prepared using propylene oxide as the lower alkylene oxide.

42. The composition of claim **30**, wherein said polyether is polyether (B) of claim **30**.

43. The composition of claim **42**, wherein said polyether is prepared using an alpha-olefin oxide having an average carbon chain length of about 20 to 30 carbon atoms, present in the amount of about 0.3 to 10 percent by weight of the total weight of said polyether, said composition forms a thermally-irreversible alginate gel composition upon contact with mammalian body tissue and/or said optional counter-ion selected from the group consisting of calcium, strontium, aluminum, and mixtures thereof, said composition is isotonic, said counter-ion, if present, is in latent form and present at an ionic compound as a microencapsulated component or present as a cation in an ion exchange resin, and said organs are situated in the peritoneal, pelvic, or pleural cavity.

44. The composition of claim **42**, wherein said polyether is prepared using an alpha-olefin oxide having an average carbon chain length of about 20 to 30 carbon atoms, present in the amount of about 0.3 to 10 percent by weight of the total weight of said polyether, said composition is isotonic, said counter-ion is the anion of an ammonium or metal salt which anion is selected from the group consisting of the phosphates, metaphosphates, pyrophosphates, tripolyphosphates, and mixtures thereof, said ionic polysaccharide is chitosan, and said counter-ion is in latent form and present as an ionic compound as a microencapsulated component or present as an anion in an ion exchange resin.

* * * * *